REVLIMID Drug Patent Profile

Which patents cover Revlimid, and when can generic versions of Revlimid launch?

Revlimid is a drug marketed by Bristol Myers Squibb and is included in one NDA. There are two patents protecting this drug and three Paragraph IV challenges.

This drug has three hundred and thirty-one patent family members in forty-one countries.

The generic ingredient in REVLIMID is lenalidomide. There are fourteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the lenalidomide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Revlimid

A generic version of REVLIMID was approved as lenalidomide by ARROW INTL on May 21^st, 2021.

Summary for REVLIMID

International Patents:	331
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for REVLIMID

Paragraph IV (Patent) Challenges for REVLIMID

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
REVLIMID	Capsules	lenalidomide	2.5 mg and 20 mg	021880	1	2016-07-12
REVLIMID	Capsules	lenalidomide	5 mg, 10 mg and 15 mg	021880	1	2010-08-30
REVLIMID	Capsules	lenalidomide	25 mg	021880	1	2010-07-12

US Patents and Regulatory Information for REVLIMID

REVLIMID is protected by two US patents and two FDA Regulatory Exclusivities.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-005	Dec 21, 2011	AB	RX	Yes	No
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-006	Jun 5, 2013	AB	RX	Yes	No			Y	Y
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-001	Dec 27, 2005	AB	RX	Yes	No
Bristol Myers Squibb	REVLIMID	lenalidomide	CAPSULE;ORAL	021880-006	Jun 5, 2013	AB	RX	Yes	No

International Patents for REVLIMID

When does loss-of-exclusivity occur for REVLIMID?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Canada

Japan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering REVLIMID around the world.

Country	Patent Number	Title	Estimated Expiration
Hong Kong	1092388
New Zealand	501429	Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines useful for reducing TNF alpha levels
Poland	195916
Spain	2340027

Supplementary Protection Certificates for REVLIMID

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0925294	SPC/GB07/047	United Kingdom		PRODUCT NAME: LENALIDOMIDE (COMMON NAME) 1-OXO-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-AMINOSOINDOLINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/07/391/001 20070619; UK EU/1/07/391/002 20070619; UK EU/1/07/391/003 20070619; UK EU/1/07/391/004 20070619
0925294	91359	Luxembourg		91359, EXPIRES: 20220614
2105135	212 50002-2015	Slovakia		PRODUCT NAME: POMALIDOMID; REGISTRATION NO/DATE: EU/1/13/850/001 - EU/1/13/850/004 20130808
0925294	C00925294/01	Switzerland		PRODUCT NAME: LENALIDOMIDUM; REGISTRATION NUMBER/DATE: SWISSMEDIC 57712 29.08.2007

REVLIMID (Lenalidomide) Investment Scenario and Fundamentals Analysis

Last updated: February 19, 2026

REVLIMID, lenalidomide, is a cornerstone oncology therapeutic with substantial market presence and a complex patent landscape. This analysis assesses its current investment standing and future prospects based on patent expiry, market dynamics, and clinical utility.

What is the Current Market Position of REVLIMID?

REVLIMID, developed by Bristol Myers Squibb (BMS), is an immunomodulatory drug (IMiD) approved for the treatment of multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma (MCL). It functions by modulating the immune system and inhibiting tumor cell proliferation.

Key Indications and Patient Populations:

• Multiple Myeloma (MM):
  • First-line treatment in combination with cyclophosphamide, bortezomib, and dexamethasone for newly diagnosed MM patients who are eligible for autologous stem cell transplant.
  • First-line treatment in combination with melphalan and prednisone for newly diagnosed MM patients who are ineligible for autologous stem cell transplant.
  • Treatment of patients with MM who have received at least one prior therapy.
  • Maintenance therapy after autologous stem cell transplant for patients with MM.
• Myelodysplastic Syndromes (MDS):
  • Treatment of patients with del(5q) MDS, with or without isolated del(5q) chromosomal abnormality, who have had at least one transfusion and in whom other therapeutic options have failed.
• Mantle Cell Lymphoma (MCL):
  • Treatment of patients with MCL who have relapsed or refractory disease, after at least one prior therapy.

The drug has achieved blockbuster status, with global net sales exceeding $12 billion in 2022 [1]. This sustained revenue generation is attributable to its efficacy across a broad spectrum of indications within hematological malignancies and its established role in treatment paradigms.

What is the Patent Landscape for REVLIMID?

The patent protection for REVLIMID has been a critical factor in its market exclusivity and profitability. BMS has strategically filed numerous patents covering the compound itself, its synthesis, formulations, and methods of use. However, the foundational patents have begun to expire, paving the way for generic competition.

Key Patent Expiries and Legal Battles:

• Compound Patent: The primary patent covering lenalidomide expired in the United States in 2017.
• Method of Use Patents: BMS has pursued additional patents for specific indications and treatment regimens. For instance, patents related to its use in MM have been subject to extensive litigation.
• Generic Entry: The first wave of generic lenalidomide entered the U.S. market in September 2022 following patent challenges and settlements. This marked a significant shift in the competitive landscape.
• European Patent Expiry: European patent expiries have also been staggered, with significant generic entry anticipated as national patents lapse.
• Litigation Strategy: BMS has engaged in numerous legal challenges to defend its patent portfolio and delay generic entry, employing strategies such as asserting secondary patents and seeking injunctions. These efforts have had varying degrees of success, influencing the timeline of generic market penetration.

The U.S. Food and Drug Administration (FDA) has approved multiple generic versions of lenalidomide, signaling the end of a significant period of market exclusivity. This transition is a primary driver of future revenue decline for BMS's branded REVLIMID.

What are the Expected Impacts of Generic Competition?

The introduction of generic lenalidomide has a profound and immediate impact on the market dynamics, pricing, and revenue streams associated with the drug.

Key Impacts:

• Price Erosion: Generic competition typically leads to substantial price reductions for drug products. Industry estimates suggest price declines of 50-80% or more within the first year of generic entry in a given market.
• Market Share Dilution: As generic alternatives become available and are often favored by payers and healthcare providers due to lower cost, the market share of branded REVLIMID will decline significantly.
• Revenue Decline for BMS: Bristol Myers Squibb's revenue from REVLIMID is projected to decrease sharply. The company has publicly acknowledged and modeled this decline in its financial forecasts. For example, BMS guided for significant REVLIMID revenue decline in 2023 and subsequent years due to generic competition [2].
• Increased Accessibility: Generic lenalidomide can improve patient access to this critical treatment, particularly in markets with stringent cost controls or where REVLIMID's price was a barrier.
• Generic Manufacturer Opportunities: The availability of generic lenalidomide presents a significant revenue opportunity for pharmaceutical companies that have successfully navigated the patent landscape and secured regulatory approvals for their generic products. Companies like Teva Pharmaceutical Industries, Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries are among those that have launched generic versions.

The rapid onset of generic competition is a predictable but impactful event that necessitates a recalibration of investment strategies related to REVLIMID.

What is the Future Clinical Utility and Development Pipeline?

Despite the impending loss of market exclusivity for the branded product, lenalidomide's clinical utility remains high, and ongoing research explores new applications and combinations.

Current and Future Clinical Relevance:

• Established Standard of Care: Lenalidomide is deeply embedded in treatment guidelines for MM, MDS, and MCL. This entrenched status ensures its continued use, albeit increasingly in generic form.
• New Combination Therapies: Research continues to explore lenalidomide in novel combination therapies, potentially expanding its efficacy or improving patient outcomes in existing indications. Studies investigating lenalidomide with newer agents in MM are ongoing.
• Exploratory Indications: While not currently approved, lenalidomide has been investigated in other hematological and oncological conditions, though significant breakthroughs in novel indications have been limited.
• Therapeutic Advancements in MM: The evolving treatment landscape for MM includes emerging cell therapies (e.g., CAR-T) and bispecific antibodies. While these represent new modalities, lenalidomide-based regimens will likely continue to play a role, particularly in earlier lines of therapy or as maintenance.

The future clinical landscape for lenalidomide will be characterized by its widespread availability as a generic, integrated into various treatment protocols, rather than as a proprietary branded product.

What are the Financial Projections and Investment Considerations?

The financial outlook for REVLIMID is dominated by the impact of generic entry. For Bristol Myers Squibb, this represents a significant revenue challenge, while for generic manufacturers, it signifies a substantial market opportunity.

Financial Outlook:

• BMS Revenue: Bristol Myers Squibb's REVLIMID revenue has been on a downward trajectory since the initial U.S. generic launches in late 2022 and is expected to decline by billions of dollars annually. Projections indicate that REVLIMID sales will fall from over $12 billion in 2022 to low single-digit billions within a few years [2].
• Generic Market Growth: The market for generic lenalidomide is expected to expand rapidly, capturing a substantial portion of the total lenalidomide market value. This growth is driven by volume increases and price competition.
• Impact on R&D Investment: As a branded product's exclusivity wanes, pharmaceutical companies often reallocate R&D resources to newer, patent-protected assets. BMS has been focusing on its pipeline in areas such as immunology and oncology.
• Valuation for Generic Manufacturers: Companies with approved generic lenalidomide products are likely to see increased revenues and potentially higher valuations, provided they can manage manufacturing scale, distribution, and pricing effectively.

Investment Considerations:

• For Investors in BMS: The declining REVLIMID revenue is a known factor and is largely priced into the company's valuation. Investors should focus on BMS's broader pipeline and growth drivers.
• For Investors in Generic Companies: The investment thesis for generic lenalidomide manufacturers hinges on their ability to gain market share, manage production costs, and achieve favorable pricing in a highly competitive market. Regulatory hurdles and successful patent challenges are prerequisites for entry.
• Market Dynamics: The speed and extent of generic price erosion, payer formulary decisions, and physician prescribing patterns will influence the pace of market shift.

The investment scenario for REVLIMID is bifurcated: a diminishing asset for its originator and a significant revenue opportunity for its generic producers.

Key Takeaways

• REVLIMID (lenalidomide) is a high-revenue oncology drug with approvals for multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma.
• Key patents protecting REVLIMID have expired, leading to the introduction of generic lenalidomide into the market, starting in the U.S. in September 2022.
• Generic competition is driving significant price erosion and market share dilution for branded REVLIMID, leading to substantial revenue declines for Bristol Myers Squibb.
• Despite patent expiries, lenalidomide retains strong clinical utility and is a standard of care, ensuring its continued use in generic forms.
• The financial outlook for REVLIMID is characterized by a sharp decline in branded sales and a corresponding rapid expansion of the generic market.
• Investment considerations are split: for BMS, managing the REVLIMID decline while advancing its pipeline; for generic manufacturers, capturing market share and profitability in a competitive environment.

Frequently Asked Questions

1. When did the first generic version of REVLIMID become available in the U.S.? The first generic lenalidomide products launched in the U.S. in September 2022.

2. What are the primary indications for which lenalidomide is approved? Lenalidomide is approved for multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma.

3. What is the expected impact of generic lenalidomide on Bristol Myers Squibb's revenue? Bristol Myers Squibb anticipates billions of dollars in annual revenue decline from REVLIMID due to generic competition.

4. Which companies are involved in the production of generic lenalidomide? Companies such as Teva Pharmaceutical Industries, Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries have launched generic lenalidomide.

5. Will lenalidomide continue to be used in clinical practice after patent expiry? Yes, lenalidomide is expected to remain a significant therapeutic option, with its use shifting to generic formulations.

Citations

[1] Bristol Myers Squibb. (2023). Bristol Myers Squibb Reports Fourth Quarter and Full Year 2022 Results. [Press release]. [2] Bristol Myers Squibb. (2023). Bristol Myers Squibb Provides 2023 Financial Guidance. [Press release].